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OBJECTIVES The study examined arterial and cardiac structure and function in bodybuilders using
androgenic anabolic steroids (AAS), compared to non-steroid-using bodybuilder controls.
BACKGROUND Adverse cardiovascular events have been reported in bodybuilders taking anabolic steroids.
The cardiovascular effects of AAS, however, have not been investigated in detail.
METHODS We recruited 20 male bodybuilders (aged 35 6 3 years), 10 actively using AAS and 10 who
denied ever using steroids. Serum lipid and hormone levels, carotid intima-media thickness
(IMT), arterial reactivity, and left ventricular (LV) dimensions were measured. Vessel
diameter was measured by ultrasound at rest, during reactive hyperemia (an endothelium-
dependent response, leading to flow-mediated dilation, FMD), and after sublingual nitro-
glycerin (GTN, an endothelium-independent dilator). Arterial reactivity was also measured in
10 age-matched non-bodybuilding sedentary controls.
RESULTS Use of AAS was associated with significant decreases in high density lipoprotein cholesterol,
sex hormone binding globulin, testosterone and gonadotrophin levels, and significant
increases in LV mass and self-reported physical strength (p , 0.05). Carotid IMT (0.60 6
0.04 mm vs. 0.63 6 0.07 mm), arterial FMD (4.7 6 1.4% vs. 4.1 6 0.7%) and GTN
responses (11.0 6 1.9% vs. 14.4 6 1.7%) were similar in both bodybuilding groups (p . 0.2).
The GTN responses were significantly lower and carotid IMT significantly higher in both
bodybuilding groups, however, compared with the non-bodybuilding sedentary controls (p 5
0.01).
CONCLUSIONS Although high-level bodybuilding is associated with impaired vascular reactivity and
increased arterial thickening, the use of AAS per se is not associated with significant
abnormalities of arterial structure or function. (J Am Coll Cardiol 2001;37:224–30) © 2001
by the American College of Cardiology
The physiologic and pharmacologic effects of androgens on
arterial structure and function are poorly characterized.
Several lines of evidence implicate a pro-atherogenic effect.
Epidemiologic studies demonstrate that cardiovascular dis-
ease is more prevalent and severe in adult men than in
women at all ages (1). Whether this disparity is due to
hormonal, genetic or lifestyle differences remains to be
clarified. Some evidence suggests androgens may be directly
involved. We have previously observed that androgens may
promote monocyte adhesion to endothelial cells (2) and
macrophage lipid loading (3). Regarding vascular function,
androgens are associated with impaired arterial reactivity in
genetic females taking high-dose androgenic steroids (4),
and endothelial function is enhanced in androgen-deprived
older men (5).
In contrast, certain observations are consistent with an
anti-ischemic effect of androgens. Testosterone is an acute
coronary vasodilator (6–8). Furthermore, although men
have greater cardiovascular risk than women (9), men with
low androgen levels have a higher risk of cardiovascular
events (10). The vascular effect of androgens is important in
assessing the potential influence of illicit androgenic ana-
bolic steroid (AAS) use on arterial structure and function in
healthy young athletes.
The use of AAS is widespread (11,12), and anecdotal
reports of premature vascular events in young AAS users
have prompted concern (13,14). However, AAS users are
difficult to study, because they are secretive about what
drugs they use and have rarely participated in voluntary
medical research. Furthermore, selection of appropriate
bodybuilding but non-AAS-using controls (matched for
type and duration of aerobic and anaerobic exercise levels) is
challenging. In this study, we investigated arterial and
cardiac structure and function in steroid-using and abstinent
young male bodybuilders, and we compared arterial struc-
ture and function to non-bodybuilding sedentary control
subjects.
METHODS
Subjects. Twenty adult male bodybuilders (age 18 to
55 years) and 10 adult male non-bodybuilding subjects
(age 27 to 48 years), all in apparent good health, were
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studied. Clinical exclusion criteria included chronic med-
ical conditions (ischemic heart disease, diabetes mellitus,
kidney, liver or psychiatric disorders) and the use of
regular cardioactive medications. All subjects gave writ-
ten informed consent, and the study was approved by the
appropriate institutional ethics review committee.
In Australia there are two major competitive bodybuild-
ing associations. Only one features frequent and mandatory
drug testing of urine samples to ensure drug-free status as a
requirement for eligibility. Bodybuilders actively using AAS
and non-AAS-using bodybuilding controls were recruited
from these two associations. In every case, self-report was
verified by urine drug testing (see below). Anabolic steroid
users were enrolled if they were currently using AAS and
had been using over a period of at least the previous 24
months. Drug-free bodybuilders denied ever using AAS,
hormonal therapy of any kind or other illicit performance-
enhancing drugs. Bodybuilding controls were included only
when there was both a negative history and negative urine
drug screen. Positive urine testing for AAS in two subjects
who denied steroid use therefore resulted in their exclusion
from further analysis. Finally a group of non-bodybuilding,
non-steroid-using controls were recruited from the commu-
nity and historically had not been on any regular exercise
program, nor ever used AAS.
Study design. This was a cross-sectional study, with study
size determined by power calculations related to the primary
end points: a comparison of flow-mediated dilation (FMD)
and left ventricular (LV) mass between bodybuilders, who
were or were not users of anabolic steroids.
Each of the bodybuilders had one study visit, during
which a history was taken, concerning health, regular
medications, steroid and other performance-enhancing drug
use, exercise patterns (hours of aerobic, anaerobic and total
exercise performed per week) and strength capacity. Supine
resting blood pressure was measured, fasting blood samples
were taken for serum hormone levels, lipids and biochem-
istry, a urine sample was taken for drug screening, two-
dimensional and Doppler echocardiography was performed,
and arterial reactivity was assessed using vascular ultrasound.
In the non-bodybuilding controls a similar history was
taken, blood tests performed, and arterial structure and
function studied, as described below.
BLOOD TESTS. Serum testosterone and estradiol levels were
measured by established immunoassays. Clinical chemistry
and lipids were measured by routine autoanalyzer methods.
URINE ASSAYS. Urine samples were screened for AAS using
gas chromatography/mass spectrometry, incorporating
modern high-resolution mass spectrometry methods, as
standardized by the International Olympic Committee (15).
VASCULAR STUDIES. Arterial reactivity was studied using
high-resolution external vascular ultrasound of the right
brachial or radial artery, as described by Celermajer et al.
(16), using a GE-Vingmed System 5 mainframe and a
10-MHz linear array transducer. Arterial diameter was
measured at rest, during reactive hyperemia (leading to
FMD, an endothelium-dependent stimulus) and after a
400-mg spray of sublingual nitroglycerin (GTN, an
endothelium-independent dilator). Reactive hyperemia re-
sponses were assessed following temporary (4.5 min) bra-
chial artery occlusion with a sphygmomanometer placed
below the target artery (cuff to 250 mm Hg). Comparing
arterial diameter measurements during reactive hyperemia
to baseline allows calculation of the values for FMD, which
is predominantly due to endothelial nitric oxide release (17).
Analysis was carried out by two independent observers.
Operators and analyzers were blinded to treatment assign-
ment, and analyzers blinded to the stage of the experiment.
Intima-media thickness (IMT) was measured using the
same ultrasound machine and transducer, for both the left
and right common carotid arteries. The image was focused
on the posterior wall, and images of the distal 10 mm of the
common carotid artery was recorded from the angle show-
ing the greatest distance between the lumen-intima inter-
face and the media-adventitia interface, as previously de-
scribed (18). The distance between the characteristic echoes
from the lumen-intima and the media-adventitia interfaces
was taken as the measure of IMT (19,20). Scans were
analyzed with a previously validated computerized edge
detection system (21). Two end-diastolic frames were se-
lected, digitized and analyzed for maximum and mean IMT;
next, the average reading was calculated from these two
frames and from the average of left and right arteries (18).
CARDIAC STUDIES. Cardiac echocardiography was per-
formed in the bodybuilders using a GE-Vingmed System 5
mainframe and a 3.5-MHz phased array transducer. Mea-
surements of LV dimensions were obtained from both
M-mode and two-dimensional echocardiography. The LV
measurements were performed at end-diastole and end-
systole according to the recommendations of the American
Society of Echocardiography and the Penn Convention
(22,23). Only frames with optimal visualization of interven-
tricular septum, posterior wall, and LV internal diameter
throughout the entire cardiac cycle were used for measure-
ments. The mean values from $3 measurements for each
parameter were computed. The LV mass was calculated
using the Devereux formula (24), and LV volumes were
Abbreviations and Acronyms
AAS 5 androgenic anabolic steroids
BP 5 blood pressure
FMD 5 flow-mediated dilation
FSH 5 follicle-stimulating hormone
GTN 5 sublingual nitroglycerin
HDL 5 high density lipoprotein
IMT 5 intima-media thickness
LH 5 luteinizing hormone
LV 5 left ventricle/left ventricular
SHBG 5 sex hormone binding globulin
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estimated using the prolate ellipsoid method (25). Doppler
assessment included the use of color, pulsed wave, and
continuous wave Doppler modes.
Statistical analysis. Descriptive data are expressed as mean
value 6 SEM. As the primary research question of this
study concerned the arterial effects of AAS use, the two
groups of bodybuilders (anabolic steroid users and drug-free
controls) were compared by independent sample t-tests or
Mann-Whitney U-tests for nonparametric variables, as
appropriate. The prospectively defined primary end points
of this study were FMD and LV mass. The p values for all
the other measured parameters were adjusted by the Hoch-
berg modification of the Bonferroni procedure for multiple
comparisons (26). Both FMD and GTN responses as well
as IMT values in the three groups (including the sedentary
controls) were tested by analysis of variance for trend (SPSS,
version 6.0), followed by the Scheffe´ test for pairwise
comparisons where appropriate. Statistical significance was
inferred at a two-sided p value ,0.05.
RESULTS
Baseline characteristics. Drug-free and AAS-using body-
builders were well matched for age, smoking history, blood
pressure and exercise regimes (hours of aerobic, anaerobic
and total exercise per week) (Table 1). There were two
smokers in the AAS group (lifetime cigarette history of 8
Pack-years each) and one smoker in the bodybuilding
control group (4 Pack-years).
Self-reported strength was significantly higher in the
AAS users (best single repetition for bench press, 150 6 16
vs. 109 6 29 kg, p 5 0.04).
The AAS users admitted using multiple agents simulta-
neously (median, 4; range, 1 to 10) for a mean duration of
6.6 6 1.4 (2 to 13) years. All users studied admitted taking
intramuscular preparations of AAS; seven users admitted
taking intramuscular preparations of testosterone esters and
four also used oral AAS preparations. At the time of study
these subjects were all currently using AAS, three in cyclical
and seven in continuous regimens. One man admitted
concomitant use of growth hormone. The most commonly
identified agents on urine drug screening were stanozolol
(70%) and nandrolone (50%). No subjects were taking other
hormonal agents, such as tamoxifen. Two subjects only were
taking creatine (one in each group of bodybuilders).
No sedentary controls were taking regular medications of
any kind. The age (34 6 2.4 years), systolic blood pres-
sure (BP) (123 6 3.8 mm Hg), total cholesterol level (4.3 6
0.3 mmol/liter), smoking history (one smoker with a 6 Pack-
years history) and vessel size (3.7 6 0.1 mm) were similar in
these sedentary controls, compared to both groups of
bodybuilding subjects (p . 0.2).
Hormone and lipid levels. Serum gonadotrophins (lutein-
izing hormone [LH], follicle-stimulating hormone [FSH])
were significantly decreased in the anabolic steroid-using
group (p 5 0.007, p 5 0.001, respectively) (Table 1). Serum
testosterone and serum sex hormone binding globulin
(SHBG) were also significantly decreased in the AAS-using
subjects (p 5 0.02, p 5 0.002, respectively).
Serum estradiol levels did not significantly differ between
the two groups of bodybuilders (p . 0.1). Total cholesterol,
triglycerides and lipoprotein(a) were similar in both groups
and within the normal ranges. Low density lipoprotein
levels did not significantly differ between the two groups of
bodybuilders; however, high density lipoprotein (HDL) was
significantly lower in the anabolic steroid group (0.6 6 0.1
vs. 1.4 6 0.1 mmol/liter, p , 0.001).
Arterial studies. The AAS users had slightly but not
significantly larger vessels than did the bodybuilder controls;
3.8 6 0.3 and 3.4 6 0.3 mm, respectively (p . 0.2) (Table
2). Despite this, FMD responses were similar in both
groups of bodybuilders; 4.7 6 1.4% and 4.1 6 0.7%,
respectively (p . 0.2). These responses tended to be lower
than FMD in the non-bodybuilding controls, but not
significantly so (7.3 6 0.7%, p 5 0.10). The GTN re-
Table 1. Baseline Characteristics in AAS Users and
Bodybuilding Controls
AAS Users
Bodybuilding
Controls
Age (yrs) 37 6 3.1 34 6 3.0
BMI 29 6 1.6 26 6 0.8
Weight (kg)* 92 6 5.0 80 6 2.4
Systolic BP (mm Hg) 127 6 2.7 119 6 3.8
Diastolic BP (mm Hg) 74 6 4.9 71 6 5.4
Total cholesterol (mmol/liter) 4.9 6 0.5 4.7 6 0.3
HDL (mmol/liter)*** 0.6 6 0.1 1.4 6 0.1
Triglycerides (mmol/liter) 1.2 6 0.2 1.0 6 0.2
Testosterone (nmol/liter)* 10.7 6 5.9 22.7 6 3.7
Estradiol (pmol/liter) 117 6 29 142 6 30
LH (U/liter)** 1.2 6 0.4 5.6 6 1.2
FSH (U/liter)*** 1.0 6 0.3 3.7 6 0.5
SHBG (nmol/liter)** 11 6 2.7 35 6 5.4
Total exercise (h/week) 9.8 6 2.1 8.0 6 1.2
Anerobic exercise (h/week) 8.8 6 1.8 6.1 6 1.0
Bench-press maximum (kg)* 150 6 16 109 6 29
AAS 5 androgenic anabolic steroids; BMI 5 body mass index; BP 5 blood pressure;
FSH 5 follicle-stimulating hormone; HDL 5 high density lipoprotein cholesterol;
LH 5 luteinizing hormone; SHBG 5 sex hormone binding globulin.
*p , 0.05. **p , 0.01. ***p , 0.001.
Table 2. Cardiovascular Results in AAS Users and
Bodybuilding Controls
AAS Users
Bodybuilding
Controls
Vessel size (mm) 3.8 6 0.3 3.4 6 0.3
FMD (%) 4.7 6 1.4 4.1 6 0.7
GTN (%) 11.0 6 1.9 14.4 6 1.7
Mean carotid IMT (mm) 0.60 6 0.04 0.63 6 0.07
Maximum carotid IMT (mm) 0.83 6 0.05 0.82 6 0.1
LV mass (g)* 245 6 16 199 6 12
IVS (mm)** 10 6 0.3 8.7 6 0.2
PW (mm)* 9.8 6 0.4 8.7 6 0.3
FS (%) 41 6 2.4 41 6 2.6
AAS 5 androgenic anabolic steroids; FMD 5 flow mediated dilatation; FS 5
fractional shortening; GTN 5 sublingual nitroglycerin; IMT 5 intima media
thickness; IVS 5 interventricular septum; LV 5 left ventricule; PW 5 posterior wall.
*p , 0.05. **p , 0.01.
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sponses were also not significantly different between the
bodybuilding groups; 11.0 6 1.9% and 14.4 6 1.7%,
respectively (p . 0.2); however, they were significantly
lower compared to non-bodybuilding controls; 19.4 6 1.4%
(p 5 0.01). Regarding arterial structure, carotid IMT results
were similar in both bodybuilding groups (0.60 6 0.04 mm
in AAS users, 0.63 6 0.07 mm in bodybuilding controls,
p . 0.2); however, these values were significantly higher
than in the non-bodybuilding controls (0.47 6 0.07 mm,
p 5 0.01).
Cardiac studies. The LV mass was significantly greater in
the AAS-using group compared to the bodybuilding con-
trols (245 6 16 and 199 6 12 g, respectively, p 5 0.04).
The LV volumes were not significantly different in these
two groups (70 6 5 and 82 6 13 cm3, p . 0.2). The LV
mass adjusted for LV volume remained significantly greater
in the AAS users (p 5 0.04); LV mass adjusted for body
surface area, however, was no longer significantly different
(117 6 7 vs. 101 6 6 g/m2, p 5 0.09). After further
adjustment for maximum strength capacity, the adjusted LV
mass was quite similar between groups (p . 0.2). There was
no significant difference in LV wall thickness or ultrasound-
assessed fractional shortening (p . 0.2). Two subjects from
the AAS group, but no controls, were noted to have mild
aortic incompetence. Resting blood pressure (BP) was
similar between groups (p . 0.2).
DISCUSSION
In this study on the cardiovascular effects of AAS use in
male bodybuilders, the major findings were a decreased level
of HDL cholesterol and a higher unadjusted LV mass in the
steroid users, but no evidence of structural or functional
abnormalities in the systemic arteries, compared to body-
building control subjects.
Anabolic steroids and metabolism. Consistent with the
findings of the current study, androgens have previously
been demonstrated to lower HDL levels significantly (27).
This is primarily due to supraphysiologic hepatic exposure
to androgens, whether by oral route or high parenteral doses
(28). Such effects on HDL cholesterol are not evident with
physiologic doses of testosterone administered transder-
mally (29) or via implants (30). This potentially pro-
atherogenic effect of AAS may be offset by a steroid-related
decrease in levels of lipoprotein(a) (31). Nevertheless, stud-
ies documenting the extent and severity of atherosclerosis in
steroid users are not available. As synthetic AASs are not
detected by routine serum testosterone assays, the observed
decrease in serum gonadotrophin levels is consistent with
net androgen overdosage in the AAS group, together with
hypothalamic-pituitary feedback inhibition. This should
also result in reduced serum testosterone levels, unless
exogenous testosterone is also being taken. The high pro-
portion (70%) using exogenous testosterone among AAS
users in this study, however, accounts for the higher than
expected mean testosterone level in this group. That is,
while subnormal serum testosterone levels were expected
and observed, the findings that mean serum testosterone
levels were actually within the normal range is consistent
with recent exogenous testosterone administration. Urine
testing and lowered serum SHBG levels (32) also serve to
confirm the self-reported status of both groups of body-
building subjects.
Effects of exercise on arterial reactivity and structure.
Regular aerobic exercise increases arterial FMD, possibly via
enhanced nitric oxide (NO) release, in both animals (33)
and in man (34). Intense aerobic exercise, however, has been
associated with impaired endothelial function (35). The use
of controls carefully matched for type and duration of
exercise is therefore an important feature of any study
designed to assess the effects of AAS (or any other drugs) in
athletes. By contrast, the effects of intense bodybuilding on
vascular reactivity are not known.
In this study, endothelium-independent dilation was
significantly reduced in both groups of bodybuilders com-
pared to sedentary controls, whereas FMD was not signif-
icantly reduced, suggesting a defect in smooth muscle
dilator capacity. Possible mechanisms include increased
water retention and/or increased vascular muscle mass
impairing smooth muscle dilator responses. This may also
account for the bodybuilding-related increase in carotid
IMT observed in this study. The possibility exists that some
or all of the bodybuilding controls have used AAS in the
past and that this had not been detected by history or urine
drug screening. This appears unlikely, however, as the
bodybuilding controls were selected from an official “drug
free” athletic society, where continued membership relies on
repeated negative urine drug screens. Furthermore, the
non-AAS-using bodybuilding controls had significantly
lower body mass, muscle strength, serum HDL and SHBG
compared to the AAS users, and normal gonadotrophin
(LH, FSH) levels, suggesting true anabolic steroid absti-
nence.
Anabolic steroids and arterial effects. Androgenic ana-
bolic steroids are used by a considerable proportion of the
community to enhance physique and performance, with
more than a million Americans using or having used
anabolic steroids (12). From this large population, there
have been case reports associating AAS and premature
cardiovascular complications including thrombo-embolic
disease (myocardial infarction, stroke and pulmonary em-
bolism), cardiomyopathy, ventricular arrhythmias and LV
hypertrophy (13,14), but it remains to be clarified if these
associations are more than chance observations.
Arterial reactivity is an important functional determinant
of vascular health or disease (36), and IMT is a structural
marker for the extent of atherosclerosis (21). Changes in
these parameters were not seen in association with AAS use
in the current study. In an experimental animal model,
chronic treatment of rabbits with the anabolic steroid
nandrolone has resulted in impairment of endothelium-
dependent and endothelium-independent dilation in aortic
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rings; however, markedly supraphysiologic doses were used
(37).
In previous human studies, androgens have had variable
effects on arterial reactivity. High-dose androgen use by
genetic females (female-to-male transsexuals) may be asso-
ciated with impaired vascular reactivity (4), and androgen
deprivation (in men having undergone castration for pros-
tate cancer) is associated with enhanced vascular reactivity
(5). Acutely administered testosterone, however, results in
vasodilatation in both animal and human studies, through
an endothelium-independent mechanism (probably via
ATP-sensitive potassium channels) (6–8). In postmeno-
pausal women, preliminary data on the use of low-dose
testosterone as part of hormone replacement therapy did not
reveal any alteration in FMD or GTN responses (38).
Finally, a case of improved forearm microvascular function
after cessation of AAS use has been reported; however, this
occurred in only one of seven such subjects examined (39).
The use of AAS in healthy young men is an unusual
situation, however, where high androgen dosage is admin-
istered without preceding androgen deficiency. This may be
important because of the prevalence of AAS usage and
preliminary reports of its potential cardiovascular risk
(13,14). The effects of AAS may be dependent on the dose,
type of androgen used and outcome measured. In this group
of young men, however, no significant arterial abnormalities
associated with AAS use were observed, suggesting a lack of
the type of deleterious effect observed in genetic females
taking high-dose androgens (4).
In our study, AAS use was associated with low HDL
levels, a potential risk factor for vascular dysfunction and
disease. In previous reports, low HDL levels have been
associated with impaired endothelial function in hypercho-
lesterolemic adults (40) and in healthy young men (41). Our
current data suggest that pharmacologically induced low
HDL levels in AAS users may not per se lead to vascular
dysfunction.
Study numbers were limited in the current report owing
to the secretive nature of AAS use in the community and
consequent reluctance to participate in medical research.
For this reason, few if any previous studies have addressed
the vascular effects of AAS use. Nevertheless, this study had
reasonable power to exclude important deleterious effects of
AAS on the systemic arteries. Our study had .80% power
to exclude a decrease of 4% in FMD in AAS users compared
with bodybuilding controls (less than the impairment ob-
served, for example, in young adult passive smokers) (42)
and a similar power to detect a difference of 0.2 mm in mean
carotid IMT between the bodybuilding groups (at the p ,
0.05 level). It is possible that studies of larger numbers of
subjects might reveal a significant reduction of FMD in all
bodybuilders (AAS using or not) compared with sedentary
controls, in addition to the GTN impairment. This would
still suggest, however, predominantly a defect in smooth
muscle rather than in endothelial function.
Anabolic steroids and the heart. There are several case
reports associating AAS use with LV hypertrophy, in-
creased LV mass, cardiomyopathy and sudden death
(13,14). In studies comparing steroid-using weightlifters
and controls, after adjusting for body surface area and
exercise capacity, there has been no significant association
noted between steroid use and LV mass or wall thickness
(43,44). Statistically significant elevation of resting systolic
BP levels in men taking AAS have previously been demon-
strated to become nonsignificant once adjusted for body
weight or biceps size, implying that this may be an artifact
of the larger arm circumference in these subjects (45). The
BP readings in the bodybuilding groups in the current study
were not significantly different and therefore seem unlikely
to account for the significant increase in LV mass seen in
AAS users. Regarding our observations of mild aortic
incompetence in two of the AAS users, there have been
previous small reports of aortic valve pathology associated
with steroid use (46); however, no large series investigating
this issue have been reported to date.
Androgens and cardiovascular disease. Androgens may
act by receptor-dependent and receptor-independent mech-
anisms. Androgen receptors are present in the cardiovascu-
lar system, including human vascular endothelium, smooth
muscle cells, macrophages and cardiac myocytes (3,47–49).
Gender differences exist in androgen receptor number and
distribution, and certain vascular effects of androgens are
gender specific (2,3). There is an important gender differ-
ence in atherosclerosis, with men having a higher risk of
clinical events at all ages (9), but whether estrogen exposure
explains the gender disparity remains unproven (50). An-
drogens may be pro-atherogenic, promoting cell adhesion
and macrophage lipid loading (2,3). Animal data, however,
are inconsistent regarding the effects of androgens on
atherogenesis and thrombosis (51–53). These data imply
complex interactions among androgens, lipids, and the
vessel wall, and further pathophysiologic studies in humans
will be required to clarify this area.
Study limitations. As outlined above, AAS users represent
a difficult group to study, both in terms of recruiting steroid
users and appropriately matched controls, as the type and
duration of exercise per se may importantly influence
vascular reactivity (54). Thus, although our study involves
few subjects, it is (to our knowledge) the first report of its
kind. Subject numbers are similar to those reported by us
previously in other unusual but interesting groups, such as
female-to-male transsexuals and androgen-deprived older
men (4,5). The AAS users had been self-administering
multiple agents, and histories regarding those dosage were
incomplete; therefore, the effects of particular steroids could
not be evaluated. Finally, although the bodybuilder groups
were closely matched for age, total cholesterol, BP and
smoking, it is possible that unmeasured differences may
have been present among the subjects.
Endothelial dysfunction is an early and important event
in atherogenesis (55). Measurement of arterial endothelial
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function has recently become established as an important
method for the detection of early arterial abnormalities in
humans (16). Arterial FMD measurements reflect predom-
inantly NO release (17) and correlate significantly with
coronary endothelial function (56) and coronary atheroscle-
rosis (57). As NO is a key mediator of arterial health, our
current findings may be reassuring regarding the vascular
effects of steroid use in otherwise healthy young men.
Nevertheless, other markers of arterial health (for example,
inflammatory cytokines) have not been assessed in this
study.
Although AAS may therefore not be associated with early
signs of arterial dysfunction or thickening, other systems
may be affected. Nonvascular health risks of AAS might
include sterility, gynecomastia, acne, balding, psychological
changes, and risks of liver abnormalities (58).
Conclusions. High-level bodybuilding is associated with
impaired vascular reactivity and increased carotid IMT, but
the use of anabolic steroids per se is not associated with
significant arterial thickening or endothelial dysfunction in
otherwise healthy young men.
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